French pharma giant Sanofi expands to battle cancer

Sanofi, a French pharmaceutical giant, has signed a deal to buy the US-based company, Amunix, which is developing novel cancer treatments that could be the key to defeating this illness.

French pharma giant, Sanofi, has bought out the American firm behind one of the most promising new cancer treatments in development.
French pharma giant, Sanofi, has bought out the American firm behind one of the most promising new cancer treatments in development. (Photo by Yann Schreiber / AFP)

French pharma giant Sanofi said Tuesday it had signed a billion-dollar deal to buy US-based biotech firm Amunix, which develops cancer treatments that enlist the body’s immune system.

“Sanofi will acquire Amunix for an upfront payment of approximately €890 million and up to €199 million upon achievement of certain future development milestones,” the French firm said in a statement.

Immuno-oncology firm Amunix is developing cancer therapies based on cytokines — small proteins that play a role in controlling the immune system — and T-cells, a type of white blood cell.

Its technology could “precisely tailor-deliver medicines to become active only in tumor tissues while sparing normal tissues,” said Sanofi research and development chief John Reed.

Its most promising candidate medicine, dubbed AMX-818, is “expected to enter the clinic in early 2022” for trials, according to Sanofi.

Amunix is the latest in a string of acquisitions by the French company, including September’s $1.6-billion buyout of US biotech firm Kadmon, which is developing treatments for transplant patients.

It also bought messenger RNA research firm Translate Bio for €2.4 billion.

Sanofi aims to complete its acquisition of Amunix in the first quarter of next year.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.


Carte vitale: France to adopt a new ‘biometric’ health card

The French parliament has approved a €20 million project to launch a 'biometric' version of the carte vitale health insurance card.

Carte vitale: France to adopt a new 'biometric' health card

As part of the French government’s package of financial aid for the cost-of-living crisis, €20 million will be set set aside to launch a biometric health card, after an amendment proposed by senators was approved.

Right-wing senators made this measure a “condition” of their support for the financial aid package, according to French left-wing daily Libération, and on Thursday the measure was approved by the Assemblée nationale.

While it sounds quite high tech, the idea is relatively simple, according to centre-right MP Thibault Bazin: the carte vitale would be equipped with a chip that “contains physical characteristics of the insured, such as their fingerprints” which would allow healthcare providers to identify them.

The carte vitale is the card that allows anyone registered in the French health system to be reimbursed for medical costs such as doctor’s appointments, medical procedures and prescriptions. The card is linked to the patient’s bank account so that costs are reimbursed directly into the bank account, usually within a couple of days.

READ ALSO How a carte vitale works and how to get one

According to the centre-right Les Républicains group, the reason for having a ‘biometric’ carte vitale is to fight against welfare fraud.

They say this would have two functions; firstly the biometric data would ensure the card could only be used by the holder, and secondly the chip would allow for instant deactivation if the card was lost of stolen.

Support for the biometric carte vitale has mostly been concentrated with right-wing representatives, however, opponants say that the implementation of the tool would be costly and lengthy.

It would involve replacing at least 65 million cards across France and repurposing them with biometric chips, in addition to taking fingerprints for all people concerned.

Additionally, all healthcare professionals would have to join the new system and be equipped with devices capable of reading fingerprints. 

Left-leaning representatives have also voiced concerns regarding the protection of personal data and whether plans would comply with European regulations for protecting personal data, as the creation of ‘biometric’ carte vitales would inevitably lead to the creation of a centralised biometric database. Additionally, there are concerns regarding whether this sensitive personal information could be exposed to cybercrime, as the health insurance system in France has been targeted by hackers in the past.

Finally, there is concern that the amount of financial loss represented by carte vitale fraud has been overestimated. The true figures are difficult to establish, but fraud related to carte vitale use is only a small part of general welfare fraud, which also covers unemployment benefits and other government subsidy schemes.

The scheme is set to begin in the autumn, but there us no information on how this will be done, and whether the biometric chip will just be added to new cards, or whether existing cards will be replaced with new ones.